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Introduction
Skin penetration with a local anesthetic is a tried method
of providing skin anesthesia and pain relief1. Several
local anesthetic preparations are now available. Lido-
caine formulated as a gel is one anesthetic that is widely
used to provide skin anesthesia before venipuncture or
incision. It can also reduce the pain associated with
other procedures, such as lumbar puncture, intramuscu-
lar injection, and even circumcision2. Although many
local anesthetics have not been approved by the United
States’ Food and Drug Administration for neuropathic
pain conditions, several historical studies suggest that
they can reduce the pain of postherpetic neuralgia3,4.
Another study found them to be of no benefit5. Topical
application of lidocaine gel is not practical, however,
for reducing sexual sensitivity.
Lidocaine is also available in a 5% patch formula-
tion that has been approved for use in postherpetic
neuralgia as the jelly form6,7. Lidocaine may also be
used in a wide variety of other instances to reduce pain
progressively, including painful polyneuropathy8 and
osteoarthritis9. In the emergency department (ED), local
anesthetic agents are one of the most commonly used
drugs. The amount of lidocaine actually absorbed is
small and well below that which leads to systemic side
effects. The safety margin is large and several patches
can be used simultaneously, with no harmful effects.
However, the central nervous system and the cardiovas-
cular system are potentially particularly susceptible to
the action of local anesthetics. The cardiovascular sys-
tem is somewhat more resistant to the adverse effects
of local anesthetics than the central nervous system.
There has been little reported on complications due
to the topical use of lidocaine, especially on its use on
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the penis to maintain erection. We report a case of
cardiac complications (chest tightness and bradycardia)
arising from systemic toxicity after topical use of lido-
caine on the penis before sexual intercourse. Emergency
physicians should be on the alert for symptoms of lido-
caine toxicity when there is a related history of topical
lidocaine application.
Case Report
The patient was a 48-year-old man who presented to
the ED of Mackay Memorial Hospital in Taiwan. He com-
plained of intermittent chest tightness without cold
sweating or radiating pain. The tightness in his chest
persisted for 2 days after spraying a large amount of
lidocaine solution on his glans before sexual activity,
which he had done during the preceding 2 weeks.
Reviewing his past clinical history, there was no indi-
cation of hyperlipidemia, diabetes mellitus or heart dis-
ease. He had smoked half a pack of cigarettes daily for
over 20 years. He denied any recent trauma.
At physical examination, the patient’s vital signs were
as follows: body temperature was 36.5°C; blood pres-
sure was 135/72 mmHg; heart rate was 53 beats per
minute; and the respiratory rate was 16 breaths per
minute. The sizes of his bilateral pupils were the same
at 3 mm in diameter with a light reflex. The conjunc-
tiva was pink. The sclera was not icteric. There were no
neck masses and the neck was supple. The lungs were
clear on auscultation. Cardiac rhythm was regular, and
there were no murmurs in the heart sounds. The abdo-
men was soft without palpable masses. The extremities
were warm and circulation was good, and there was
no pitting edema. There was no erosion, swelling or
pus seen on the glans.
We performed an electrocardiogram (ECG) and labo-
ratory studies. The ECG revealed a small P wave and
sinus bradycardia (Figure). Laboratory results were nor-
mal: troponin I was less than 0.10 ng/mL; creatine
kinase MB was 2.6 U/L; creatine kinase was 109 IU/L;
potassium was 4.4 mEq/L. The patient had no history
of heart disease, and his previous ECGs had shown
normal patterns. After excluding all of the most possible
leading causes, we concluded that the complaints of
chest tightness and the presentation of bradycardia on
the ECG were most likely caused by the overuse of top-
ical lidocaine, applied to the glans, which was then
absorbed to produce general toxicity.
During a period of observation lasting several hours,
the patient’s condition stabilized. No drugs were given.
Bradycardia still persisted on the ECG, but the patient
ceased complaining of chest tightness. He was dis-
charged 3 hours later. Before he left the ED, the
patient was advised on the contraindications of lido-
caine use. It was also suggested to this patient that he
immediately return to the ED if he should again expe-
rience the adverse effects of lidocaine, including chest
tightening and bradycardia. Even though this patient
recovered without any medication, a cardiovascular
follow-up visit was arranged.
Discussion
Lidocaine is one of the most widely used local anesthetic
agents in the ED. Topical anesthetics, unlike injectable
anesthetics, can be applied painlessly and can provide
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Figure. The presentation of patient’s electrocardiogram after topical application of lidocaine.
sufficient pain control to maintain patient comfort
throughout many procedures. Use of topical lidocaine
is considered relatively safe10–17; but some instances of
adverse events have been reported. Amitai et al.18 re-
ported a fatal overdose in a boy aged 13 months fol-
lowing ingestion of an oral lidocaine preparation. Upon
admission, the serum lidocaine level of the boy was
found to be 19.5μg/mL. The boy was treated with me-
chanical ventilation and brain resuscitation but did not
regain consciousness, and died approximately 50 days
after overdose.
Promisloff and DuPont19 reported delayed hypoten-
sion and tachycardia with cardiovascular collapse, and
adult respiratory distress syndrome following the admin-
istration of less than 30 mL of 1% lidocaine solution for
topical anesthesia prior to fiberoptic bronchoscopy.
Mofenson et al.20 reported that a male infant aged
11 months developed seizures and had a plasma lido-
caine concentration of 10μg/mL, following the applica-
tion of 2% viscous lidocaine to his gums 5–6 times daily
for a week.
Therapeutic levels of lidocaine are 1–5μg/mL.
Toxicity may sometimes occur at therapeutic drug levels.
Serious poisoning may occur at lidocaine levels above
5μg/mL. Lidocaine toxicity affects many systems21–24.
In the cardiovascular system, it depresses cardiac con-
duction and contractility, causing dysrhythmias (sinus
bradycardia, atrioventricular junctional or ventricular
bradycardia, second- or third-degree heart block, asys-
tole, and rarely ventricular tachycardia or fibrillation
resulting from re-entrant mechanisms)10,25–27.
In our case, the patient, who had no history of heart
attack, was healthy prior to this incident. He had only
once been hospitalized because of a left inguinal her-
nia, and had shown heart stress tightness and abnormal
sinus rhythm on the ECG, with a heart rate of around
53 beats per minute. We presumed that the cause of
the cardiovascular episode in this patient was the top-
ical application of lidocaine to his penis, which was
related to the adverse effects, although no data was
supplied from laboratory studies. In previous reports,
severe bradycardia and even cardiac arrest have been
found in healthy patients following neuraxial anesthe-
sia, with a reported incidence of cardiac arrest of 6.4 per
10,000 patients associated with spinal anesthesia. How-
ever, there are no studies reporting only on the incidence
of complications resulting from topical anesthesia. In
such cases, prompt diagnosis, immediate cardiopulmo-
nary resuscitation and aggressive vasopressor therapy
with epinephrine (adrenaline) are required28. After re-
viewing this case, we speculate that the adverse effects
caused by topical use of lidocaine are not as serious 
as those caused by systemic use. Many previous re-
ports have indicated that lidocaine dermal absorption
takes about 3.5 hours (ranging from 2.0 to 5.9 hours),
and it is 95% metabolized by the liver; less than 10% is
excreted unchanged in the urine and the elimination
half-life is 1.5–2 hours. The treatment of bradycardia
related to lidocaine toxicity is essentially supportive. The
airway should be maintained and oxygen is necessary
in symptomatic bradycardia, while monitoring of blood
pressure and continuous ECG is mandatory in the ED.
Recovery from bradycardia is usually automatic without
aggressive treatment, but if persistent hypotension or
relatively unstable signs are exhibited, atropine and car-
diac pacing are indicated29–33. When bradycardia occurs,
causing hemodynamic disturbances, only treatment
with atropine is indicated. When cardiac arrest occurs,
cardiopulmonary resuscitation must be performed.
The main treatments include oxygen, sodium bicar-
bonate, adrenaline, calcium, and perhaps glucagon.
This must be continued until symptoms resolve34.
In conclusion, this case highlights the fact that
emergency physicians should consider toxicity as a
possible diagnosis when patients present with cardiac
symptoms, especially with prior administration of top-
ical anesthetic agents. Topical lidocaine toxicity is very
rare, but that does not mean it is not possible. The im-
portance of detailed history taking is the key point to
be taken from this case. Rapid and accurate diagnosis
results in the avoidance of unwarranted treatment and
undue distress to the patient. In the case of an inexact
diagnosis, medical resources could be wasted on need-
less procedures and unnecessary medication.
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